Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted at Fudan University’s Huashan ...

Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing pressures on drugs. China’s out-licensing deals ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug powerhouse and has become one of the world’s most successful female ...

SML Biopharm Co. Ltd. is harnessing mRNA technology to develop novel immunotherapy-based cancer vaccines, including two ...

In an about-face, Sarepta Therapeutics Inc. said it would “voluntarily and temporarily” pause all shipments of Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec) in the U ...

Cancer cells often use epigenetic changes to resist treatment, a major factor particularly in late-stage deaths from ovarian cancer. One potential epigenetic marker, DNA secondary structures known as ...

Immune evasion continues to limit the effectiveness of cancer immunotherapies. Among emerging regulatory molecules, transfer RNA-derived small RNAs (tsRNAs of 13-48 nucleotides), generated through ...

Cyclin-dependent kinase 9 (CDK9) plays a critical role in regulating transcriptional elongation and is essential for the expression of short-lived oncogenic and antiapoptotic mRNAs. Targeting CDK9 has ...

The U.S. organ donation system is once again under pressure from both the executive and legislative branches thanks to media ...

Following up on the $175 million it raised in September 2023, Avalyn Pharma Inc. secured an additional $100 million in an ...

The U.K. Medicines and Healthcare Products Regulatory Agency unveiled another round of measures designed to promote access to the latest medical technology, which includes a move to jettison domestic ...

Deepqure Inc. gained clinical trial clearance from South Korea’s Ministry of Food and Drug Safety to test its Hyperqure renal denervation system for the treatment of atrial fibrillation.